Selected article for: "blood sample and design study"

Author: Croxford, Sara; Emanuel, Eva; Ibitoye, Ayeshat; Njoroge, Jacquelyn; Edmundson, Claire; Bardsley, Megan; Heinsbroek, Ellen; Hope, Vivian; Phipps, Emily
Title: Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services
  • Cord-id: lppfvfu1
  • Document date: 2021_1_15
  • ID: lppfvfu1
    Snippet: Objective To describe the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on people who inject drugs (PWID) in England, Wales and Northern Ireland. Study design Cross-sectional unlinked anonymous monitoring (UAM) Survey of PWID. Methods People who had ever injected psychoactive drugs were recruited to the UAM Survey by specialist drug/alcohol services in England, Wales and Northern Ireland. From June 2020, in addition to providing a dried blood spot sample and
    Document: Objective To describe the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on people who inject drugs (PWID) in England, Wales and Northern Ireland. Study design Cross-sectional unlinked anonymous monitoring (UAM) Survey of PWID. Methods People who had ever injected psychoactive drugs were recruited to the UAM Survey by specialist drug/alcohol services in England, Wales and Northern Ireland. From June 2020, in addition to providing a dried blood spot sample and completing the UAM behavioural questionnaire, participants were asked to complete an enhanced coronavirus disease (COVID-19) questionnaire. Preliminary data are presented to the end of October and were compared to data from the 2019 UAM Survey, where possible. Results Between June and October, 288 PWID were recruited from England and Northern Ireland. One in nine (11%; 29/260) PWID reported testing positive for SARS-CoV-2 or experiencing COVID-19 symptoms. Fifteen percent (26/169) reported injecting more frequently in 2020 compared to 2019; cocaine injection in the preceding four weeks increased from 17% (242/1,456) to 25% (33/130). One in five PWID (22%; 35/188) reported difficulties in accessing HIV and hepatitis testing and one in four (26%; 47/179) reported difficulties in accessing equipment for safer injecting. Conclusions Our preliminary findings suggest that PWID have experienced negative impacts on health, behaviours and access to essential harm reduction, testing and treatment services due to the COVID-19 pandemic. Continued monitoring through surveillance and research is needed to understand the subsequent impact of COVID-19 on blood-borne virus transmission in this population and on health inequalities.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1
    Co phrase search for related documents, hyperlinks ordered by date